Capranico G, Riva A, Tinelli S, Dasdia T, Zunino F
Cancer Res. 1987 Jul 15;47(14):3752-6.
DNA single-strand and double-strand breaks produced by doxorubicin and two anthracycline derivatives (4-demethoxy-daunorubicin and 4'-deoxy-4'-iododoxorubicin) were measured in doxorubicin-sensitive and -resistant P388 leukemia cell lines, using filter elution methods, and compared with cellular drug accumulation to account for major differences in their cytotoxic activities and cross-resistance. The increased cytotoxic potency of the two derivatives reflects at least in part the enhanced drug accumulation by cells that results from their increased lipophilicity. However, the level of protein-linked DNA breaks was not directly related to cellular accumulation of drug analogues. It is possible that enhanced cytotoxicity may also be the consequence of the greatly enhanced ability of analogues to cause DNA strand breaks. The resistant line showed only a modest degree of resistance to both anthracycline derivatives compared with the high degree of resistance to doxorubicin. Although for all the anthracyclines tested drug accumulation was reduced in the resistant line, this did not correlate with the degree of resistance. A differential sensitivity of resistant and parental cell lines to DNA cleavage activity was consistently found for all three drugs tested. However, in contrast to a lack of effect of doxorubicin, the derivatives caused appreciable DNA strand breakage in resistant cells. The enhanced ability of these analogues to break DNA in resistant cells is consistent with the slight cross-resistance with doxorubicin. DNA double-strand breaks produced in isolated nuclei from these cells paralleled the pattern found in whole cells, thus indicating that a nuclear alteration, presumably involving DNA topoisomerases, is associated with anthracycline resistance. Our findings strongly support the hypothesis that anthracycline resistance in these cell variants may be mediated by multiple mechanisms, involving alterations of plasma membrane and changes of nuclear enzymatic activities responsible for DNA strand breaks.
使用滤膜洗脱法,在对阿霉素敏感和耐药的P388白血病细胞系中,检测了阿霉素及两种蒽环类衍生物(4-去甲氧基柔红霉素和4'-脱氧-4'-碘阿霉素)产生的DNA单链和双链断裂情况,并将其与细胞药物蓄积进行比较,以解释它们细胞毒性活性和交叉耐药性的主要差异。两种衍生物细胞毒性效力的增强至少部分反映了由于其亲脂性增加导致细胞对药物蓄积的增强。然而,蛋白质连接的DNA断裂水平与药物类似物的细胞蓄积并无直接关联。增强的细胞毒性也可能是类似物导致DNA链断裂能力大幅增强的结果。与对阿霉素的高度耐药相比,耐药细胞系对两种蒽环类衍生物仅表现出适度的耐药性。尽管对于所有测试的蒽环类药物,耐药细胞系中的药物蓄积均减少,但这与耐药程度并无关联。对于所有三种测试药物,始终发现耐药细胞系和亲本细胞系对DNA切割活性存在差异敏感性。然而,与阿霉素无作用相反,这些衍生物在耐药细胞中导致了明显的DNA链断裂。这些类似物在耐药细胞中增强的DNA断裂能力与对阿霉素的轻微交叉耐药性一致。从这些细胞的分离细胞核中产生的DNA双链断裂与在完整细胞中发现的模式相似,因此表明一种可能涉及DNA拓扑异构酶的核改变与蒽环类耐药相关。我们的研究结果有力地支持了这样一种假说,即这些细胞变体中的蒽环类耐药可能由多种机制介导,包括质膜改变和负责DNA链断裂的核酶活性变化。